Saltar al contenido
Fuerza y músculoEstudio transversal3 min read

A quick physical-performance test can screen for severe sarcopenia but misses precision

Colectivo editorial MoveVitals · Study published · Reading updated

Original paper:The diagnostic value of the Short Physical Performance Battery for sarcopenia. · BMC geriatrics · 2020 · Artículo original ↗

Idea principal

In 294 community-dwelling adults aged 65 and over, the Short Physical Performance Battery (SPPB) had moderate accuracy for sarcopenia (AUC 0.644 to 0.770), and a cut-point of 8 points or less caught 82-100% of severe cases but had only 36-41% specificity. Sarcopenia was rare (4 to 16%), so many people flagged would not have it.

Study design

Estudio transversal

Reading basis

Published abstract

Reading focus

Association & confounding

Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.

Pregunta de investigación

Sarcopenia, the age-related loss of muscle mass, strength and function, is rarely diagnosed in clinics because the diagnostic process is labor-intensive. The SPPB is a quick, objective test of strength and physical performance, so the authors checked how well it identifies sarcopenia, alone and combined with lean mass.

Población y método

Cross-sectional analysis of 294 community-dwelling older persons (65 years and over). Appendicular lean body mass divided by height squared (ALM/h²), muscle strength (handgrip and sit-to-stand) and physical performance (gait speed, timed up and go, and SPPB) were measured with validated procedures. Sarcopenia was diagnosed using both the EWGSOP1 and EWGSOP2 criteria. Diagnostic ability of the SPPB, alone and combined with ALM/h², was judged by area under the curve (AUC), with candidate cut-points and their sensitivity and specificity.

Resultados

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Sarcopenia prevalence ranged from 4 to 16% depending on the definition used.
  2. 2
    The SPPB had moderate value for diagnosing sarcopenia, with AUC between 0.644 and 0.770.
  3. 3
    A cut-point of 8 points or less gave high sensitivity (82-100%) but low specificity (36-41%) for severe sarcopenia.
  4. 4
    The authors conclude the SPPB has acceptable value for severe sarcopenia and could be a screening tool where lean mass measurement is not available.

Límites e incertidumbre

  1. 1
    Only 294 people were studied at one point in time, and severe sarcopenia was uncommon, so the sensitivity estimates rest on few cases.
  2. 2
    Low specificity (36-41%) means many people without severe sarcopenia would also test positive, so it works as a screen, not a diagnosis.
  3. 3
    Results depend on which definition (EWGSOP1 or EWGSOP2) is used, so they cannot be applied uniformly.
  4. 4
    This reading is based on the abstract only, which gives no confidence intervals for the AUCs or cut-point results.

Relevancia práctica

A short chair-rise, walking and balance test is a reasonable first step to flag older adults who may need further assessment for sarcopenia, but a score of 8 or lower does not by itself mean someone has it. Anyone concerned about muscle weakness should have it assessed by a clinician.

Tus datos

You can approximate parts of this at home, such as timing how long it takes to stand up from a chair repeatedly or tracking usual walking speed on a device. These are not the formal test, so use them only to compare yourself with your own earlier results under the same conditions, not as a diagnosis.

Cómo interpretar la evidencia

Measurements are taken in the same period. Direction and causation usually cannot be determined; symptoms can change behaviour as well as the reverse.

Resumen estructurado de los autores English

El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.

Background

Sarcopenia is defined as the age-related loss of muscle mass, strength, and physical performance. The original European Working Group on Sarcopenia in Older Persons (EWGSOP1) definition, and its revision (EWGSOP2), provide new cut-points and alternate measures for sarcopenia diagnosis. However, sarcopenia is rarely diagnosed in clinical settings owing to its labor-intensive diagnostic process. Given the Short Physical Performance Battery (SPPB) is a quick, easily administrable, and objective measure of muscle strength and physical performance, both of which are key components of sarcopenia, this study examined the diagnostic value of the SPPB for this muscle disease.

Methods

A cross-sectional analysis of 294 community-dwelling older persons (≥65 years) was conducted. Appendicular lean body mass [(ALM) divided by height squared (ALM/h^(2))], muscle strength (handgrip/sit to stand), and physical performance [gait speed, timed up and go (TUG) and SPPB] were assessed using validated procedures, while participants were diagnosed with sarcopenia following the EWGSOP1 and EWGSOP2 criteria. Diagnostic ability of the SPPB independently and combined with ALM/h^(2) for sarcopenia was determined using area under the curve (AUC). Potential cut-points were identified, and sensitivity and specificity calculated.

Results

Prevalence of sarcopenia ranged from 4 to 16% depending on the definition. The SPPB demonstrated moderate (AUC = 0.644-0.770) value in diagnosing sarcopenia, and a cut-point of ≤8points in SPPB performance resulted in high sensitivity (82-100%) but low specificity (36-41%) for diagnosing those with severe sarcopenia.

Conclusions

The SPPB displayed acceptable value in diagnosing older adults with severe sarcopenia. Moreover, the high sensitivity of the SPPB when using the cut-point of ≤8 suggests it may be a favorable screening tool for sarcopenia in clinical settings where ALM measurements are not available.

Fuentes y atribución

The diagnostic value of the Short Physical Performance Battery for sarcopenia.

Phu S, Kirk B, Bani Hassan E, Vogrin S, Zanker J, Bernardo S, Duque G.

BMC geriatrics · 2020-07-13

DOI: 10.1186/s12877-020-01642-4 ↗PubMed · 32660438 ↗Europe PMC · Licencia registrada: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada

Fuentes verificadas 2026-11-01

Guías prácticas

Leer en contexto

·Revisión de revisiones

ACSM review of 137 reviews: resistance training works, and few programme details matter

The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.

Medicine & Science in Sports & Exercise

Explicaciones detalladasLeer estudio →
·Metaanálisis de ensayos

Nearly every resistance training plan beat no exercise; heavy loads led for strength

In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
·Metaanálisis observacional

Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes

Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
·Metaanálisis de ensayos

Protein supplements and weight training: small extra gains, smaller in older adults

Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
Fuerza y músculo →